Vivian Ortiz
@VivianOrtizMD
Transplant Hepatologist @WUGastro via @MayoClinicGIHep @PennGIHep @YaleIMed | #runner. Views are my own
ID:922559922172321796
23-10-2017 20:26:40
2,6K Tweets
2,1K Followers
1,6K Following
ZeNan Li Chang, MD, PhD, WashU Gastroenterology Washington U. Med received the 2024 @amergastroassn Fellowship-to-Faculty Transition Award.
The AGA program serves as a catalyst for career growth among the most promising researchers in gastroenterology and hepatology.
More> l8r.it/tBS4
Getting ready for Digestive Disease Week?
Here is our annual sneak peek at our IMIBD programming to help you prepare!
We have focused more than ever on investigator-initiated research as well as novel clinical and basic talks and symposia including:
- 5 state-of-the art basic,
New Review - Piano et al - Infections in cirrhosis
thelancet.com/journals/langa…
#LiverTwitter #IDTwitter #Cirrhosis Salvatore Piano Sebastian Marciano
📚 #ReadoftheWeek CMGH
👉🏻Neonatal Colonic Inflammation (NI) Epigenetically Aggravates Epithelial Injury in Adults
🔑NI sensitizes the colon to injury
🔑NI ⬆️ IL1β activation by hyperacetylation
🔑Mediated by NFkB
🔑B-blocker ⬇️ injury
#GITwitter
cmghjournal.org/article/S2352-…
New Nature Medicine
The longest randomized trial assessment—4 years— of semaglutide (Wegovy) in participants without diabetes
nature.com/articles/s4159…
Sustained weight loss, no new side effects noted
🆕 Review in CMGH!
🔄Interplay between #DILI and #GutMicrobiota - A Comprehensive Overview
#LiverTwitter 🤝 #GITwitter
👀Read it now at the link below!
#OpenAccess = #CMGH4ALL
cmghjournal.org/article/S2352-…
Precision treatment in advanced HCC
Cancer Cell
doi.org/10.1016/j.ccel…
👏Excellent summary on precision medicine in HCC
👉all you need to know on molecular classification, biomarker, iTME & future directions...
ESMO - Eur. Oncology EASL Education ILCA #livertwitter
The history of HCC therapy. Proudly written to honor those that have been key players to move the field forward. Looking back allows to step into the future without outdated issues and some major problems already solved.
pubmed.ncbi.nlm.nih.gov/38707239/ Hospital Clínic IDIBAPS CIBERehd
Safety & feasibility of CTx followed by liver transplantation for pts with definitely unresectable
CRC liver mets
eClinicalMedicine – The Lancet Discovery Science
doi.org/10.1016/j.ecli…
🔎 TransMet trail
🤔Interesting, highlights the challenges in this field
👉meticulous selection process is key
🧐LT outcome
Biliary tract cancers: 🇫🇷 national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
doi.org/10.1016/j.ejca…
👏comprehensive recommandations
ESMO - Eur. Oncology ILCA EASL Education
🔥off the press: Durvalumab + gemcitabine/cisplatin in advanced biliary tract cancer: patient-reported outcomes from TOPAZ-1
The Lancet Oncology
👉No improvement yet, but adding Durva has no detrimental effect and some long-term benefit
Author link👇
authors.elsevier.com/c/1j02A5EIIgPd…
ESMO - Eur. Oncology
Ready, set, network! 🫱🏽🫲🏿 Join us for meetups at 📍 AGA Central (L Street Bridge) at #DDW2024 and reconnect with your #AGAGastroSquad or make new connections during Digestive Disease Week!
All networking events 👉🏽 ow.ly/K4vA50Rr28K
RSVP 👉🏽 ow.ly/FYMU50Rr28I
#HEP_highlights : Refractory Hepatic Hydrothorax: An Ominous Sign of End-Stage Liver Disease
Chin A et al. Refractory HH is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites
#LiverTwitter
tinyurl.com/4jfs4ce7
Pre-transplant Use of Immune Checkpoint Inhibitors for HCC
American Journal of Transplantation
doi.org/10.1016/j.ajt.…
🔎 RWD🇨🇳, 83 pts
👉27.7% developed allograft rejection, mortality: 6/83
👉≥ 30 days before TX protective
🤔feasible, but relevant risk
ESMO - Eur. Oncology ILCA EASLnews #livertwitter
Olympic Champion ✅
London Marathon Champion ✅
Amazing run from Peres Jepchirchir!
#LondonMarathon